<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04913532</url>
  </required_header>
  <id_info>
    <org_study_id>2020-q12</org_study_id>
    <nct_id>NCT04913532</nct_id>
  </id_info>
  <brief_title>Hypofractionation With Simultaneous Integrated Boost for Early Breast Cancer</brief_title>
  <official_title>A Phase II Trial of Evaluation of Acute Toxicity in Hypofractionation With Simultaneous Integrated Boost for Early Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Capital Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Capital Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Simultaneous integrated boost radiotherapy has been investigated in some malignant tumors and&#xD;
      appears to be safe and feasible. However, Hypofractionation with simultaneous integrated&#xD;
      boost has been investigating in breast cancer.&#xD;
&#xD;
      Investigators initiated this phase II prospective trial to analyse acute toxicity of&#xD;
      hypofractionation with simultaneous integrated boost in patients with early breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hypofractionated radiotherapy of the breast 15 × 2.70 Gy with simultaneous integrated boost&#xD;
      to the tumor bed (total dose within the boost volume 15 × 3.20 Gy)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 22, 2021</start_date>
  <completion_date type="Anticipated">July 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Acute Toxicity</measure>
    <time_frame>6 months</time_frame>
    <description>Acute skin radiogenic toxicity grade II or higher according to NCI-CTCAE</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Feasibility of the radiation plan</measure>
    <time_frame>19 days</time_frame>
    <description>Dose constraints Dmean lung &lt; 10 Gy; Dmean heart &lt; 5 Gy, Dmedian contralateral breast &lt; 4Gy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>other acute Toxicity</measure>
    <time_frame>0-6 months</time_frame>
    <description>All dimensions of NCI-CTCAE/RTOG</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Skin toxicity (Cosmetic results)</measure>
    <time_frame>0 to 6 months</time_frame>
    <description>RTOG</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Surgery</condition>
  <condition>Adjuvant Radiotherapy</condition>
  <arm_group>
    <arm_group_label>Hypofractionation with SIB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hypofractionation with SIB</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Hypofractionation with simultaneous integrated boost</intervention_name>
    <description>Hypofractionation with simultaneous integrated boost</description>
    <arm_group_label>Hypofractionation with SIB</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histopathologically confirmed breast cancer operated by breast conserving surgery with&#xD;
             clear margins&#xD;
&#xD;
          -  Indication to adjuvant radiotherapy including boost radiotherapy&#xD;
&#xD;
          -  Clearly identified primary tumor region preferably by radiopaque clips&#xD;
&#xD;
          -  Primary wound healing after breast conserving therapy without signs of infection&#xD;
&#xD;
          -  Pre- and/or postoperative chemotherapy and endocrine therapy were permitted when&#xD;
             indicated&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients operated by mastectomy&#xD;
&#xD;
          -  No indication for boost radiation&#xD;
&#xD;
          -  Resection margins positive for disease or insufficient identification of the boost&#xD;
             volume&#xD;
&#xD;
          -  Indication for radiotherapy of the regional lymph nodes&#xD;
&#xD;
          -  History of prior breast or thoracic radiotherapy&#xD;
&#xD;
          -  Extended postoperative seroma at the beginning of radiotherapy&#xD;
&#xD;
          -  Psychiatric disorders or psychological disabilities thought to adversely affect&#xD;
             treatment compliance&#xD;
&#xD;
          -  Pregnant or lactating patients and woman of child bearing potential, who lacked&#xD;
             effective contraception&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wenjie Ni, MD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Shijitan Hospital, Capital Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wenjie Ni, MD.</last_name>
    <phone>8613661171730</phone>
    <email>niwenjie_1990@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Shijitan Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100038</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wenjie Ni</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>May 30, 2021</study_first_submitted>
  <study_first_submitted_qc>May 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 4, 2021</study_first_posted>
  <last_update_submitted>August 25, 2021</last_update_submitted>
  <last_update_submitted_qc>August 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Capital Medical University</investigator_affiliation>
    <investigator_full_name>Wenjie Ni</investigator_full_name>
    <investigator_title>Capital Medical University</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

